VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study (Q39001886)

8 September 2017

VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study (English)

1 reference

8 September 2017

8

1 reference

8 September 2017

9

1 reference

8 September 2017

Pauliina Hartiala

3

0 references

Mikko T Visuri

series ordinal

1

object named as

Mikko T Visuri

1 reference

8 September 2017

10

Anne M Saarikko

1 reference

8 September 2017

2

Krista M Honkonen

1 reference

8 September 2017

4

Tomi V Tervala

1 reference

8 September 2017

Paavo J Halonen

5

1 reference

PubMed ID

26018927

8 September 2017

Heikki Junkkari

series ordinal

6

1 reference

PubMed ID

26018927

8 September 2017

Nina Knuutinen

series ordinal

7

1 reference

8 September 2017

28 May 2015

1 reference

8 September 2017

1 reference

8 September 2017

18

1 reference

8 September 2017

3

1 reference

8 September 2017

313-326

1 reference

https://scigraph.springernature.com/pub.10.1007/s10456-015-9469-2

8 September 2017

0 references

cites work

Lymphangiogenesis in development and human disease

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Biological basis of therapeutic lymphangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Overview of surgical treatments for breast cancer-related lymphedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Circumferential suction-assisted lipectomy for lymphoedema after surgery for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Treatment of lymphedema with lymphaticovenular anastomoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Treatment of various secondary lymphedemas by microsurgical lymph vessel transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

The influence of afferent lymphatic vessel interruption on vascular addressin expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Growth Factor Therapy and Autologous Lymph Node Transfer in Lymphedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Lymph node transfer and perinodal lymphatic growth factor treatment for lymphedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Lymphangiogenic gene therapy with minimal blood vascular side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Experimental assessment of pro-lymphangiogenic growth factors in the treatment of post-surgical lymphedema following lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Molecular mechanisms and clinical applications of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Molecular biology and pathology of lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

The propeptides of VEGF-D determine heparin binding, receptor heterodimerization, and effects on tumor biology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Blood vessel endothelial VEGFR-2 delays lymphangiogenesis: an endogenous trapping mechanism links lymph- and angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Growth factor therapy and autologous lymph node transfer in lymphedema.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-015-9469-2

10.1007/S10456-015-9469-2

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference

PubMed ID

26018927